Selected article for: "convalescent serum and hyperimmune immunoglobulin"
Author: Gupta, Ankur; Karki, Rashmi; Dandu, Himanshu R; Dhama, Kuldeep; Bhatt, Madan LB; Saxena, Shailendra K
Title: COVID-19: benefits and risks of passive immunotherapeutics
  • Cord-id: fdzm9xp5
  • Document date: 2020_9_22
    • ID: fdzm9xp5
    Snippet: Passive immunotherapeutics (PITs), including convalescent plasma, serum, or hyperimmune immunoglobulin, have been of clinical importance during sudden outbreaks since the early twentieth century for the treatment of viral diseases such as severe acute respiratory syndrome (SARS), middle east respiratory syndrome (MERS) and swine flu (H1N1). With the recent SARS-CoV-2 pandemic, wherein effective antivirals and vaccines are still lacking, an interest in convalescent plasma therapy as a lifesaving
    Document: Passive immunotherapeutics (PITs), including convalescent plasma, serum, or hyperimmune immunoglobulin, have been of clinical importance during sudden outbreaks since the early twentieth century for the treatment of viral diseases such as severe acute respiratory syndrome (SARS), middle east respiratory syndrome (MERS) and swine flu (H1N1). With the recent SARS-CoV-2 pandemic, wherein effective antivirals and vaccines are still lacking, an interest in convalescent plasma therapy as a lifesaving option has resurfaced due to its capacity for antigenic neutralization and reducing viremia. This review summarizes convalescent blood products (CBPs) in terms of current technologies and the shortcomings related to the collection, manufacture, pathogen inactivation, and banking of CBPs, with a specific focus on their plausible applications, benefits, and risks in the COVID-19 pandemic.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
    • abdominal pain and liver transplant: 1, 2, 3, 4
    • abdominal pain and low number: 1
    • abdominal pain and low quality: 1, 2, 3
    • abdominal pain and lung injury: 1, 2, 3, 4, 5
    • abdominal pain and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • access program and acute trali lung injury: 1
    • access program and liver transplant: 1
    • access program and lung injury: 1, 2
    • access program and lymphocyte count: 1
    • action mode and ade antibody dependent enhancement: 1
    • action mode and liver disease: 1, 2, 3
    • action mode and low quality: 1
    • action mode and lung lesion: 1